Eli Lilly And Company Announces Post-Hoc Analyses Of ATTAIN-1 Showing Foundayo Is Associated With Significant Reductions In Predicted 10-Year Risk Of Type 2 Diabetes And Cardiovascular Disease
Eli Lilly announced post-hoc analyses of ATTAIN-1 showing Foundayo reduced predicted 10-year risk of type 2 diabetes and cardiovascular disease. At 72 weeks, reductions were 45.0%, 50.0%, and 57.0% for diabetes and 18.0% for cardiovascular disease at different doses. Foundayo is FDA-approved for weight management.
How this was made
The 30-second read
Why it matters
The post‑hoc risk‑reduction figures provide new evidence of cardiovascular and diabetes benefits, which could expand the drug's market and support pricing power.
Market read
First disclosure of significant trial data for a major obesity drug; likely to affect Lilly's valuation and the broader GLP‑1 market.
What to watch
Regulatory review timelines and competitive pipeline (e.g., Novo Nordisk, Pfizer) could moderate impact.
Background
Foundayo (orforglipron) is Lilly's oral GLP‑1 agonist approved for obesity; the ATTAIN‑1 Phase 3 trial evaluated three dose levels over 72 weeks.
Ticker impact
Eli Lilly released post‑hoc ATTAIN‑1 analyses showing its obesity drug Foundayo cuts 10‑year diabetes and cardiovascular risk, a new efficacy data point.
likely upside as market prices in the risk‑reduction results
First disclosure of significant trial outcomes for a large‑cap obesity drug; data are material and could drive sales growth.
Market effects
Obesity/weight‑loss therapeutics sector may see heightened investor interest and valuation uplift.
U.S. and global markets could react as the drug is approved in multiple regions.
Potentially influences biotech and pharma indices worldwide.
Counterpoint
If the data do not translate into real‑world outcomes or reimbursement, the stock may not benefit.
Key entities
- companyEli Lilly and Company
Pharmaceutical company developing Foundayo.
- companyChugai Pharmaceutical Co. Ltd.
Original discoverer of orforglipron, licensor to Lilly.
